Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

67%

2 of 3 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

N/A

2(40.0%)

Phase 2

1(20.0%)

5Total

Phase 3(2)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06844487Phase 3Active Not Recruiting

Phase 3 Infant Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT06844500Phase 3Active Not Recruiting

Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC

Role: collaborator

NCT03243396Not ApplicableCompleted

Building and Sustaining Interventions for Children: Task-sharing Mental Health Care in Low-resource Settings

Role: collaborator

NCT04186000Phase 2Completed

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

Role: collaborator

NCT01822366Not ApplicableCompleted

Randomized Controlled Trial of Trauma-focused CBT in Tanzania and Kenya

Role: collaborator

All 5 trials loaded